König S, Hirneiß C W
Augenklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität, Mathildenstr. 8, 80336, München, Deutschland.
Ophthalmologe. 2018 Aug;115(8):670-675. doi: 10.1007/s00347-017-0565-0.
The STARflo Glaucoma Device (iSTAR Medical, Wavre, Belgium) offers a new approach to bleb-free filtering surgery in which the intraocular pressure (IOP) is lowered by supporting outflow of the aqueous humor into the suprachoroidal space.
On the basis of a case series of 9 patients with open-angle glaucoma (OAG) unmanageable by drug-based treatment, intra- and postoperative experiences with the implant are presented. The implant, the implantation procedure, and the first results 6 months postoperatively are described.
No intraoperative complications were observed. Postoperative complications such as increased astigmatism or ocular hypotony were rare and transient. After 6 months there was an IOP reduction from 29.1 mm Hg ± 6.1 mm Hg with 2.7 ± 1.1 local IOP-lowering medications to 16.1 ± 4.1 mm Hg (IOP reduction of 44.7%) with additional 2.0 ± 0.8 local IOP-lowering medications.
The new STARflo Glaucoma Device shows promising results in reducing the IOP of medically uncontrolled OAG. Further investigations concerning the long-time efficacy of the implant and additional IOP-lowering medication are still ongoing.
STARflo青光眼装置（iSTAR Medical，比利时瓦夫尔）为无滤过泡滤过手术提供了一种新方法，该方法通过支持房水流入脉络膜上腔来降低眼压。
基于9例药物治疗无法控制的开角型青光眼（OAG）患者的病例系列，介绍了植入该装置的术中及术后体验。描述了该植入物、植入过程以及术后6个月的初步结果。
未观察到术中并发症。术后并发症如散光增加或低眼压很少见且为短暂性。6个月后，眼压从使用2.7±1.1种局部降眼压药物时的29.1±6.1毫米汞柱降至使用另外2.0±0.8种局部降眼压药物时的16.1±4.1毫米汞柱（眼压降低44.7%）。
新型STARflo青光眼装置在降低药物治疗无法控制的OAG眼压方面显示出有前景的结果。关于该植入物的长期疗效以及额外降眼压药物的进一步研究仍在进行中。
